Announcement on Authorizing the Chairman to Decide on Entrusting Financial Management
Release time:
2020-08-05
证券简称:尖峰集团 证券代码:600668 编号:临2018-007
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于授权董事长决定委托理财的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
●委托理财金额:授权董事长行使不超过人民币3亿元的委托理财的决策权,在该额度内资金可以滚动使用,但任一时点存续的委托理财余额合计不得超过3亿元。
●委托理财投资类型:选择安全性高、流动性好、低风险的品种开展委托理财业务。
●委托理财期限:每笔投资业务的期限均不得超过12个月。
一、概述
(一)基本情况
1、原则:以“规范运作、防范风险、谨慎投资、保值增值”为原则。
2、品种:选择安全性高、流动性好、低风险的品种开展委托理财业务。
3、资金:自有资金。
4、授权额度、期限:授权董事长行使不超过人民币3亿元的委托理财的决策权,在该额度内资金可以滚动使用,但任一时点存续的委托理财余额合计不得超过3亿元。每笔委托理财的期限不得超过 12个月。授权期限自公司本次董事会审议通过之日起3年内有效。具体投资活动由公司财务部负责组织实施。
5、实施方式:授权董事长决定在上述额度内的委托理财投资相关事宜,包括但不限于:选择合格专业理财机构、选择具体的委托理财产品品种、明确委托理财金额及期限、签署相关合同及协议等。
(二)公司内部需履行的审批程序
2018年4月20日,公司第十届董事会第三次会议审议通过了《关于授权公司董事长利用自有资金进行委托理财的议案》。表决结果:同意9票、反对0票、弃权0票。
二、主要内容
(一)委托资金来源:自有资金。
(二)对公司的影响
1、公司的委托理财,是在确保公司日常运营和资金安全的前提下实施的,不影响公司日常资金周转,不影响公司经营业务的正常开展。
2、通过进行适度的低风险的理财产品投资业务,可以提高资金使用效率,能获得一定的投资效益,为公司股东谋取更多的投资回报。
(三)风险控制分析
公司严格按照《委托理财管理制度》审批和执行程序,确保委托理财等投资业务的有效开展和规范运行。但由于金融市场受经济环境的影响较大,不排除投资理财等投资业务会受到市场波动的影响,公司将采取以下措施:
(1)公司明确专人负责该等投资事项的相关工作:公司董事长行使该等投资决策权并签署相关合同文件,公司财务负责人负责组织实施,财务部负责具体操作。
(2)公司财务部负责及时分析和跟踪理财产品投向、投资项目进展情况,如评估发现存在可能影响公司资金安全或影响正常资金流动需求的状况,将及时采取相应保全或赎回措施,以控制投资风险。
(3)公司审计部门负责对各项投资情况进行审计与监督,定期对委托理财的进展情况、盈亏情况、风险控制等情况进行审计、核实,并根据谨慎性原则对各项委托理财可能的风险与收益进行评价,向董事会审计委员会报告。
(4)公司严格按照中国证监会及上海证券交易所的相关规定履行信息披露义务。
(四)独立董事意见
公司独立董事对该项决议发表了独立意见,认为:该决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
三、截至本公告日,公司累计委托理财的情况
|
序号 |
受托人 |
理财产品类型 |
金额 (万元) |
起始日 |
到期日 |
截止公告日已收回本金金额(万元) |
截止公告日获得收益(万元) |
|
1 |
广发银行金华分行 |
薪加薪16号5876人民币结构性存款产品 |
5,000.00 |
2017/4/6 |
2017/7/5 |
5,000.00 |
51.16 |
|
2 |
渤海银行金华分行 |
渤海银行S17180号结构性存款理财产品 |
3,000.00 |
2017/5/17 |
2017/6/19 |
3,000.00 |
10.58 |
|
3 |
渤海银行金华分行 |
渤海银行S17265号结构性存款理财产品 |
3,000.00 |
2017/6/23 |
2017/7/27 |
3,000.00 |
12.30 |
|
4 |
广发银行金华分行 |
薪加薪16号J0253人民币结构性存款产品 |
4,000.00 |
2017/7/6 |
2017/10/9 |
4,000.00 |
44.66 |
|
5 |
广发银行金华分行 |
薪加薪16号J352人民币结构性存款产品 |
4,000.00 |
2017/7/28 |
2017/11/13 |
4,000.00 |
50.66 |
|
6 |
广发银行金华分行 |
薪加薪16号XJXCKJ0577人民币结构性存款产品 |
4,000.00 |
2017/9/14 |
2017/11/29 |
4,000.00 |
36.06 |
|
7 |
招商银行金华江北支行 |
招商银行结构性存款CHZ00318 |
3,000.00 |
2017/10/10 |
2017/11/13 |
3,000.00 |
10.76 |
|
8 |
渤海银行金华分行 |
渤海银行S17480号结构性存款理财产品 |
4,000.00 |
2017/10/12 |
2017/11/14 |
4,000.00 |
14.36 |
|
9 |
民生银行金华分行 |
与利率挂钩的结构性存款产品 |
3,000.00 |
2018/1/5 |
2018/2/14 |
3,000.00 |
14.79 |
|
10 |
渤海银行金华分行 |
渤海银行S17686号结构性存款理财产品 |
3,000.00 |
2018/1/9 |
2018/2/12 |
3,000.00 |
12.27 |
|
11 |
招商银行金华江北支行 |
招商银行结构性存款CHZ00473号 |
3,000.00 |
2018/4/3 |
2018/5/28 |
|
|
|
12 |
广发银行金华分行 |
薪加薪16号人民币结构性存款产品 |
4,000.00 |
2018/4/3 |
2018/5/28 |
|
|
|
13 |
渤海银行金华分行 |
渤海银行S18283号结构性存款理财产品 |
3,000.00 |
2018/4/4 |
2018/5/29 |
|
|
|
14 |
招商银行金华江北支行 |
招商银行结构性存款CHZ00483号 |
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11